In vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis

摘要: Background: Several animal and few human studies suggest the beneficial role of bone marrow mesenchymal stem cells (MSCs) in liver cirrhosis. However, little is known about fate MSCs after infusion cirrhotic patients. We evaluated cell biodistribution peripheral four Methods: After three passages MSCs, patients received a total 250–400×10 6 cells, which only 50% were labeled. Specific activities 0.21–0.67 MBq/10 maintained for injected labeled MSCs. Planar whole-body acquisitions (anterior/ posterior projections) acquired immediately following as well at 2 h, 4 24 48 7th 10th days infusion. Results: intravenous infusion, radioactivity was first observed to accumulate lungs. During hours days, gradually increased spleen, with spleen uptake exceeding that all Region-of-interest analysis showed percentage homing (following decay background corrections geometric mean calculation) from 0.0%-2.8% post-infusion images 13.0–17.4% 10th-day post-infusion. Similarly, residual 2.0%-10.2% 30.1%-42.2% same period, lungs decreased 27.0–33.5% 2.0–5.4%. Conclusion: The 111 In-oxine through vein safe Cell labeling